Page 171 - எங்களுக்கு தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy se in , - y with other steroids . A sequence of studies investigated the safety, tolerability and long-term treatment benefit with vamorolone and provide open-label data in a total of 46 patients with DMD, aged 4 to up to 10 years (start/end of treatment), of which 41 (89%) completed a 2.5 years treatment period. 48 participants initially completed a two-week multiple ascending dose trial VBP15-002 [1], 46 of whom entered the open-label 6-month extension VBP15-003 [2], covering a dose range of vamorolone of 0.25 to 6.0 mg/kg/day. All of the 46 patients completing the latter study entered the 24-month long-term extension study VBP15-LTE [3] where all patients eventually received doses of vamorolone of 2.0 to 6.0 mg/kg/day. The total exposure to vamorolone treatment in these studies was 113 patient years. The most commonly administere

Switzerland generalUnited statesUnited kingdomEric hoffmanEva kaliasReveragen biopharmaDario eklundReveragen biopharma incSanthera pharmaceuticalsInternational neuromuscular research groupMuscular dystrophy association united statesNational institutes of healthHead external communicationsEuropean commission horizonDuchenne research fundFoundation to eradicate duchenne